← Leaderboards
Elena Nikolaevna Pugacheva
West Virginia University
$4,838,202
Attributed
$4,838,202
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $631.1K · FY2010–22$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$4,838,202 · 5
By mechanism
R01$3,220,536 · 1
P20$1,108,791 · 2
R21$358,875 · 1
R03$150,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsMolecularBaseXenograft ModelNeoplastic CellTumor ProgressionOverexpressionCellsSignal TransductionRegulationTumor GrowthReportingProteinsNeoplasm MetastasisCancer TherapyPathway InteractionsPhosphorylationMalignant Breast NeoplasmIn VitroTumor XenograftInhibitor/AntagonistAffectHdac6 Gene
Grant awards (20)
Patient-derived Xenograft Core Facility (PDXCF)$174,089
P20 · FY2022 · GM · contact PI
Patient-derived Xenograft Core Facility (PDXCF)$174,180
P20 · FY2021 · GM · contact PI
The role of HEF1/NEDD9 protein in proliferation and invasion of metastatic breast cancer$356,250
R01 · FY2020 · CA · contact PI
Patient-derived Xenograft Core Facility (PDXCF)$171,786
P20 · FY2020 · GM · contact PI
The role of HEF1/NEDD9 protein in proliferation and invasion of metastatic breast cancer$345,562
R01 · FY2019 · CA · contact PI
Patient-derived Xenograft Core Facility (PDXCF)$169,824
P20 · FY2019 · GM · contact PI
Developing a system for PDX in vivo genetic manipulation and selection$75,000
R03 · FY2019 · CA · contact PI
The role of HEF1/NEDD9 protein in proliferation and invasion of metastatic breast cancer$356,250
R01 · FY2018 · CA · contact PI
Patient-derived Xenograft Core Facility (PDXCF)$199,824
P20 · FY2018 · GM · contact PI
Developing a system for PDX in vivo genetic manipulation and selection$75,000
R03 · FY2018 · CA · contact PI
The role of HEF1/NEDD9 protein in proliferation and invasion of metastatic breast cancer$356,250
R01 · FY2017 · CA · contact PI
The role of KIF2C/AURKA signaling in cilia loss and progression of glioblastoma.$163,125
R21 · FY2017 · CA · contact PI
The role of HEF1/NEDD9 protein in proliferation and invasion of metastatic breast cancer$356,250
R01 · FY2016 · CA · contact PI
The role of KIF2C/AURKA signaling in cilia loss and progression of glioblastoma.$195,750
R21 · FY2016 · CA · contact PI
The role of HEF1 protein in division and invasion of metastatic breast cancer$286,022
R01 · FY2014 · CA · contact PI
The role of HEF1 protein in division and invasion of metastatic breast cancer$277,176
R01 · FY2013 · CA · contact PI
The role of HEF1 protein in division and invasion of metastatic breast cancer$294,868
R01 · FY2012 · CA · contact PI
The role of HEF1 protein in division and invasion of metastatic breast cancer$294,868
R01 · FY2011 · CA · contact PI
The role of HEF1 protein in division and invasion of metastatic breast cancer$297,040
R01 · FY2010 · CA · contact PI
THE ROLE OF HEF1 PROTEIN IN INVASION OF METASTATIC BREAST CANCER$219,088
P20 · FY2010 · RR · contact PI